Dynavax Technologies (NASDAQ:DVAX) Shares Gap Down to $11.03

Dynavax Technologies Co. (NASDAQ:DVAX - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $11.03, but opened at $10.60. Dynavax Technologies shares last traded at $10.83, with a volume of 314,645 shares traded.

Analyst Upgrades and Downgrades

Several research analysts have commented on DVAX shares. HC Wainwright restated a "buy" rating and issued a $29.00 price objective on shares of Dynavax Technologies in a report on Thursday, May 9th. StockNews.com lowered shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Friday, April 26th. The Goldman Sachs Group started coverage on shares of Dynavax Technologies in a research note on Thursday, February 1st. They issued a "neutral" rating and a $20.00 price target for the company. Finally, William Blair reiterated an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 23rd. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Dynavax Technologies currently has a consensus rating of "Moderate Buy" and an average target price of $25.33.

Dynavax Technologies Stock Down 0.3 %

The company's 50-day moving average is $11.95 and its 200 day moving average is $12.95. The company has a market capitalization of $1.44 billion, a PE ratio of 183.83 and a beta of 1.30. The company has a debt-to-equity ratio of 0.36, a quick ratio of 14.10 and a current ratio of 15.20.

Insider Activity at Dynavax Technologies

In related news, CAO Justin Burgess sold 20,526 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $12.78, for a total transaction of $262,322.28. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.98% of the stock is currently owned by insiders.

Institutional Trading of Dynavax Technologies

A number of institutional investors have recently made changes to their positions in the stock. CANADA LIFE ASSURANCE Co boosted its holdings in shares of Dynavax Technologies by 4.1% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 150,265 shares of the biopharmaceutical company's stock valued at $1,866,000 after acquiring an additional 5,934 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Dynavax Technologies by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 9,402,246 shares of the biopharmaceutical company's stock valued at $116,682,000 after acquiring an additional 126,458 shares during the last quarter. Mizuho Markets Americas LLC boosted its holdings in shares of Dynavax Technologies by 16.9% in the first quarter. Mizuho Markets Americas LLC now owns 852,057 shares of the biopharmaceutical company's stock worth $10,574,000 after buying an additional 123,300 shares during the last quarter. ProShare Advisors LLC boosted its holdings in shares of Dynavax Technologies by 8.3% in the first quarter. ProShare Advisors LLC now owns 35,269 shares of the biopharmaceutical company's stock worth $438,000 after buying an additional 2,691 shares during the last quarter. Finally, ClariVest Asset Management LLC boosted its holdings in shares of Dynavax Technologies by 11.5% in the first quarter. ClariVest Asset Management LLC now owns 108,752 shares of the biopharmaceutical company's stock worth $1,350,000 after buying an additional 11,235 shares during the last quarter. Hedge funds and other institutional investors own 96.96% of the company's stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.